LBEC0101

DRUG3 trials

Sponsors

LG Life Sciences

Conditions

Arthritis, RheumatoidHealthyRheumatoid Arthritis

Phase 1

Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25 mg With Those of Enbrel®

CompletedNCT01145950

LG Life SciencesHealthy

Start: 2010-06-30End: 2011-01-31Target: 36Updated: 2011-02-18

Phase 3

A Study Comparing LBEC0101 to Enbrel® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy

LG Life SciencesArthritis, Rheumatoid

Start: 2015-02-28Target: 372Updated: 2016-01-06

A Study to Evaluate the Long-term Safety and Efficacy of LBEC0101 in Subjects With Active RA Despite Methotrexate (MTX)

CompletedNCT02715908

LG Life SciencesRheumatoid Arthritis

Start: 2016-04-30End: 2018-04-30Updated: 2018-07-06

Related Papers

Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study.

2019-05-2118 citations

Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate.

2017-12-1934 citations